CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Acrigen Biosciences
Main focus: Next-generation safe gene-editing therapies
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Berkeley, CA, USA
Website: https://www.acrigen.com/
Acrigen Biosciences develops novel high precision gene-editing systems. The company seeks to identify and develop next-generation CRISPR-Cas nucleases using its proprietary AcrTAIN™ bioinformatics discovery software platform. The company also develops its proprietary ErAcr proteins - Engineered Recombinant Anti-CRISPR proteins - that selectively inhibit off-target editing. The company raised seed funding in September 2021.
